Time trends in human papillomavirus prevalence and genotype distribution in vulvar carcinoma in Norway [PDF]
Acta Obstetricia et Gynecologica Scandinavica, 2023 Introduction Approximately 25%–43% of all vulvar carcinomas are associated with human papillomavirus (HPV). In many countries, vulvar carcinoma incidence rates are increasing, possibly due to greater HPV exposure.
Christin Julia Meltzer‐Gunnes +6 more
doaj +4 more sources
HPV-independent vulvar squamous cell carcinoma: a case report and review of the literature [PDF]
Einstein (São Paulo)Vulvar cancer, a rare gynecological malignancy, accounts for 3-5% of cases and is most commonly squamous cell carcinoma. Prognosis is poorer in cancers unrelated to human papillomavirus (HPV), often associated with chronic inflammation.
Raphael Federicci Haddad +6 more
doaj +4 more sources
Vulvar neuroendocrine carcinoma that is independent of merkel cell polyomavirus and human papillomavirus suggests endometrial cancer recurrence: a case report [PDF]
BMC Endocrine Disorders, 2022 Background Vulvar neuroendocrine carcinomas with small cell morphology need an appropriate differential diagnosis with respect to primary Merkel cell carcinomas, primary small cell neuroendocrine carcinomas, and secondary/metastatic carcinomas.
Tomoko Hirakawa +4 more
doaj +2 more sources
The Therapy of Vulvar Carcinoma—Evaluation of Surgical Options in a Retrospective Monocentric Study [PDF]
Life, 2023 (1) Background: Surgical-oncological treatment methods are continuously put to the test in times of evidence-based medicine—notably, a constant reevaluation remains key, especially for tumor entities with increasing incidence such as vulvar carcinoma. (2)
Peter Jankowski +7 more
doaj +2 more sources
Recurrent herpes simplex virus mimicking vulvar carcinoma in patient with Human Immunodeficiency Virus: A case report [PDF]
Gynecologic Oncology Reports, 2023 Patients with human immunodeficiency virus (HIV) are at increased risk for developing other gynecologic conditions, including herpes simplex virus (HSV) and vulvar intraepithelial neoplasia (VIN)/carcinoma.
Rachel McKean +4 more
doaj +2 more sources
WNL we never looked: vulvar carcinoma incidence after screening cutoff [PDF]
International Journal of Women's DermatologyThe incidence of vulvar carcinoma increases with age, though elderly women receive less aggressive cancer therapies and fewer strategies aimed at cancer prevention.
Amaris N. Geisler, MD, Jodi E. Ganz, MD
doaj +2 more sources
HPV16 viral characteristics in primary, recurrent and metastatic vulvar carcinoma [PDF]
Papillomavirus Research, 2018 Vulvar carcinoma is the fourth most common gynecological malignancy. Two separate carcinogenic pathways are suggested, where one is associated with the human papillomavirus (HPV) and HPV16 the most common genotype.The aim of this study was to evaluate ...
Gabriella Lillsunde Larsson +4 more
doaj +2 more sources
Circulating Hsa-miR-431-5p as Potential Biomarker for Squamous Cell Vulvar Carcinoma and Its Premalignant Lesions [PDF]
Diagnostics, 2021 Vulvar squamous cell carcinoma (VSCC) develops from high-grade squamous intraepithelial lesions (HSIL) and differentiated vulvar intraepithelial neoplasia (dVIN).
Mateusz Bujko +8 more
doaj +2 more sources
Case report: A kidney metastasis from vulvar squamous cell carcinoma [PDF]
Frontiers in OncologyIntroductionDistant metastases of vulvar SCC most commonly involve the lung, liver, bone, skin, and lymph nodes. Metastasis from vulvar SCC to the kidneys is extremely rare, with only one case reported in the literature to date.Case presentationWe report
Junwei He +11 more
doaj +2 more sources
Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines [PDF]
Gynecologic Oncology Reports, 2022 There are limited treatment options for patients with advanced vulvar cancer. However, several immune checkpoint inhibitors (ICIs) are FDA-approved or NCCN-Compendia–listed for qualified patients with advanced disease.
Aaron Praiss +5 more
doaj +2 more sources